Skip to main content

Table 2 Adverse events reported by HCQ group

From: Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial

Adverse event

Frequency (n = 34)

Headache

11 (32.3)

Dyspepsia

10 (29.4)

Nausea

8 (23.5)

Myalgia

8 (23.5)

Anorexia

5 (14.7)

Dizziness

3 (8.8)

Low back pain

2 (5.8)

Palpitations

1 (2.9)

  1. Values are n (%)
  2. HCQ hydroxychloroquine
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us